

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6852600

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST
CONVEYING PARTY DATA	
Name	Execution Date
NEURELIS, INC.	08/05/2021
AEGIS THERAPEUTICS, LLC	08/05/2021
RECEIVING PARTY DATA	
Name:	ORBIMED ROYALTY & CREDIT OPPORTUNITIES III, LP
Street Address:	601 LEXINGTON AVENUE, 54TH FLOOR
Internal Address:	C/O ORBIMED ADVISORS LLC
City:	NEW YORK
State/Country:	NEW YORK
Postal Code:	10022
PROPERTY NUMBERS Total: 62	
Property Type	Number
Patent Number:	8551468
Patent Number:	8927497
Patent Number:	9642913
Patent Number:	9114069
Patent Number:	8329220
Patent Number:	8470370
Patent Number:	8883728
Patent Number:	8642564
Patent Number:	8268791
Patent Number:	8440631
Patent Number:	9283280
Patent Number:	10512694
Patent Number:	7425542
Patent Number:	8076290
Patent Number:	8084022
Patent Number:	7998927
Patent Number:	8133863
Patent Number:	8772231

Property Type	Number
Patent Number:	8226949
Patent Number:	8846044
Patent Number:	9446134
Patent Number:	10046025
Patent Number:	9895444
Patent Number:	10265402
Application Number:	16898365
Patent Number:	8173594
Application Number:	16311944
Application Number:	17024149
Application Number:	16461354
Application Number:	17055647
Application Number:	16721872
Application Number:	16615362
Application Number:	15890131
Application Number:	16420044
Application Number:	16678347
Application Number:	16869461
Application Number:	16875683
PCT Number:	US2020033201
Application Number:	63115845
Application Number:	63135291
Application Number:	63115847
Application Number:	63115848
Application Number:	63115849
Patent Number:	8530463
Application Number:	16594897
Patent Number:	8895546
Patent Number:	9763876
Application Number:	17228514
Application Number:	17332800
Application Number:	17336389
Application Number:	63209089
Application Number:	63185807
Application Number:	63209092
Patent Number:	7572913
Patent Number:	9687483
Patent Number:	10149856

Property Type	Number
Patent Number:	10857157
Application Number:	17114335
Patent Number:	10106525
Patent Number:	10526313
Application Number:	16735359
Patent Number:	10537567

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Email: akwon@cov.com

Correspondent Name: COVINGTON & BURLING LLP

Address Line 1: ONE CITY CENTER, 850 TENTH ST NW

Address Line 2: ATTN: PATENT DOCKETING

Address Line 4: WASHINGTON, D.C. 20001

ATTORNEY DOCKET NUMBER:	034550.00075
NAME OF SUBMITTER:	ASHLEY M. KWON
SIGNATURE:	/Ashley M. Kwon/
DATE SIGNED:	08/06/2021

Total Attachments: 13

source=OrbiMed-Neurelis - Patent Security Agreement Executed#page1.tif
source=OrbiMed-Neurelis - Patent Security Agreement Executed#page2.tif
source=OrbiMed-Neurelis - Patent Security Agreement Executed#page3.tif
source=OrbiMed-Neurelis - Patent Security Agreement Executed#page4.tif
source=OrbiMed-Neurelis - Patent Security Agreement Executed#page5.tif
source=OrbiMed-Neurelis - Patent Security Agreement Executed#page6.tif
source=OrbiMed-Neurelis - Patent Security Agreement Executed#page7.tif
source=OrbiMed-Neurelis - Patent Security Agreement Executed#page8.tif
source=OrbiMed-Neurelis - Patent Security Agreement Executed#page9.tif
source=OrbiMed-Neurelis - Patent Security Agreement Executed#page10.tif
source=OrbiMed-Neurelis - Patent Security Agreement Executed#page11.tif
source=OrbiMed-Neurelis - Patent Security Agreement Executed#page12.tif
source=OrbiMed-Neurelis - Patent Security Agreement Executed#page13.tif

PATENT SECURITY AGREEMENT

This PATENT SECURITY AGREEMENT, dated as of August 5, 2021 (this "Agreement"), is made by Neurelis, Inc., a Delaware corporation (the "Borrower"), and Aegis Therapeutics, LLC, a California limited liability company (together with the Borrower, each a "Grantor" and collectively, the "Grantors"), in favor of ORBIMED ROYALTY & CREDIT OPPORTUNITIES III, LP, a Delaware limited partnership (together with its Affiliates, successors, transferees and assignees, the "Lender").

W I T N E S S E T H :

WHEREAS, pursuant to the Credit Agreement, dated as of August 5, 2021 (as amended, supplemented or otherwise modified from time to time, the "Credit Agreement"), by and between the Borrower and the Lender, the Lender has extended Commitments to make Loans to the Borrower;

WHEREAS, in connection with the Credit Agreement, the Grantors and their Affiliates have executed and delivered a Pledge and Security Agreement in favor of the Lender, dated as of August 5, 2021 (as amended, supplemented or otherwise modified from time to time, the "Security Agreement");

WHEREAS, pursuant to the Credit Agreement and pursuant to clause (f) of Section 4.5 of the Security Agreement, each Grantor is required to execute and deliver this Agreement and to grant to the Lender a continuing security interest in all of the Patent Collateral (as defined below) to secure all of the Obligations; and

WHEREAS, each Grantor has duly authorized the execution, delivery and performance of this Agreement;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each Grantor agrees, for the benefit of the Lender, as follows:

SECTION 1. Definitions. Unless otherwise defined herein or the context otherwise requires, terms used in this Agreement, including its preamble and recitals, have the meanings provided (or incorporated by reference) in the Security Agreement.

SECTION 2. Grant of Security Interest. Each Grantor hereby grants to the Lender, for its benefit, a continuing security interest in all of such Grantor's right, title and interest in and to the Patent Collateral, including each patent and patent application referred to in Item A of Schedule I attached hereto and each patent license referred to in Item B of Schedule I attached hereto.

SECTION 3. Security Agreement. This Agreement has been executed and delivered by each Grantor for the purpose of registering the security interest of the Lender in the Patent Collateral with the United States Patent and Trademark Office. The security interest granted hereby has been granted in furtherance of, and not in limitation of, the security interest granted to the Lender for its benefit under the Security Agreement. The Security Agreement (and all rights

and remedies of the Lender thereunder) shall remain in full force and effect in accordance with its terms.

SECTION 4. Release of Liens. Upon (a) the Disposition of Patent Collateral in accordance with the Credit Agreement or (b) the occurrence of the Termination Date, the security interests granted herein shall automatically terminate with respect to (i) such Patent Collateral (in the case of clause (a)) or (ii) all Patent Collateral (in the case of clause (b)). Upon any such Disposition or termination, the Lender will, at such Grantor's sole expense, deliver to such Grantor, without any representations, warranties or recourse of any kind whatsoever, all Patent Collateral held by the Lender hereunder, and execute and deliver to such Grantor such documents as such Grantor shall reasonably request to evidence such termination.

SECTION 5. Acknowledgment. Each Grantor does hereby further acknowledge and affirm that the rights and remedies of the Lender with respect to the security interest in the Patent Collateral granted hereby are more fully set forth in the Security Agreement, the terms and provisions of which (including the remedies provided for therein) are incorporated by reference herein as if fully set forth herein.

SECTION 6. Loan Document. This Agreement is a Loan Document executed pursuant to the Credit Agreement and shall (unless otherwise expressly indicated herein) be construed, administered and applied in accordance with the terms and provisions thereof, including Article X thereof.

SECTION 7. Governing Law. THIS AGREEMENT AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY DOCUMENT CONTEMPLATED HEREBY SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK (INCLUDING FOR SUCH PURPOSE SECTIONS 5-1401 AND 5-1402 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK). This Agreement, along with the other Loan Documents, constitutes the entire understanding among the parties hereto with respect to the subject matter thereof and supersedes any prior agreements, written or oral, with respect thereto.

SECTION 8. Effectiveness. This Agreement shall become effective when a counterpart hereof executed by the Grantors, shall have been received by the Lender. Delivery of an executed counterpart of a signature page to this Agreement by email (e.g., "pdf" or "tiff") or telecopy shall be effective as delivery of a manually executed counterpart of this Agreement.


[Signature Page Follows.]

IN WITNESS WHEREOF, the Grantor hereto has caused this Agreement to be duly executed and delivered by its Authorized Officer as of the date first above written.

NEURELIS, INC.

By: 
Name: George Stuart
Title: Chief Financial Officer

AEGIS THERAPEUTICS, LLC

By: Neurelis, Inc., its sole member

Name: George Stuart
Title: Chief Financial Officer

SCHEDULE I
to Patent Security Agreement

Item A. Patents.

Case Number	Sub Case	Country	Application No.	Filing Date	Patent No.	Issue Date	Expiration / Expected Expiration Date (if pending)	Title	Owner Name	Status
148570.002	41OB	United States of America	12/189722	11-Aug-2008	8551468	08-Oct-2013	06-Apr-2026	ABSORPTION ENHANCERS FOR INTRANASAL INTERFERON ADMINISTRATION	Aegis Therapeutics, LLC	Granted
148570.002	51OB	United States of America	13/371274	10-Feb-2012	8927497	06-Jan-2015	21-Jul-2025	ABSORPTION ENHANCERS FOR INTRANASAL ADMINISTRATION	Aegis Therapeutics, LLC	Granted
148570.002	61OB	United States of America	14/152686	10-Jan-2014	9642913	09-May-2017	11-May-2025	PHARMACEUTICAL COMPOSITION INCLUDING ALKYL GLYCOSIDE AND AN ANTI-SEIZURE AGENT	Aegis Therapeutics, LLC	Granted
148570.002	71OB	United States of America	12/512862	30-Jul-2009	9114069	25-Aug-2015	02-Jun-2026	ANTIBACTERIAL COMPOSITIONS FOR DRUG ADMINISTRATION	Aegis Therapeutics, LLC	Granted
148570.010	01	United States of America	12/197179	22-Aug-2008	8329220	11-Dec-2012	26-Nov-2029	CONTROLLED RELEASE FORMULATIONS	Aegis Therapeutics, LLC; UAB Research Foundation	Granted
148570.010	11	United States of America	13/688116	28-Nov-2012	8470370	25-Jun-2013	22-Aug-2028	CONTROLLED RELEASE FORMULATIONS	Aegis Therapeutics, LLC; UAB Research Foundation	Granted
148570.011	21	United States of	12/954219	24-Nov-2010	8883728	11-Nov-2014	17-Jun-2026	INTRANASAL ADMINISTRATION OF ACTIVE	Aegis Therapeutics, LLC	Granted

Case Number	Sub Case	Country	Application No.	Filing Date	Patent No.	Issue Date	Expiration / Expected Expiration Date (if pending)	Title	Owner Name	Status
		America						AGENTS TO THE CENTRAL NERVOUS SYSTEM		
148570.012	11OB	United States of America	12/036963	25-Feb-2008	8642564	04-Feb-2014	01-Aug-2028	COMPOSITIONS FOR DRUG ADMINISTRATION	Aegis Therapeutics, LLC	Granted
148570.012	31OB	United States of America	12/341696	22-Dec-2008	8268791	18-Sep-2012	09-May-2026	ALKYLGLYCOSIDE COMPOSITIONS FOR DRUG ADMINISTRATION	Aegis Therapeutics, LLC	Granted
148570.012	41OB	United States of America	12/645376	22-Dec-2009	8440631	14-May-2013	22-Nov-2026	COMPOSITIONS FOR DRUG ADMINISTRATION	Aegis Therapeutics, LLC	Granted
148570.012	51OB	United States of America	13/893219	13-May-2013	9283280	15-Mar-2016	01-Jul-2025	COMPOSITIONS FOR DRUG ADMINISTRATION	Aegis Therapeutics, LLC	Granted
148570.012	91OB	United States of America	15/655669	20-Jul-2017	10512694	24-Dec-2019	11-May-2025	COMPOSITIONS FOR ORAL DRUG ADMINISTRATION	Aegis Therapeutics, LLC	Granted
148570.013	01	United States of America	11/474055	23-Jun-2006	7425542	16-Sep-2008	23-Jun-2026	STABILIZING ALKYLGLYCOSIDE COMPOSITIONS AND METHODS THEREOF	Aegis Therapeutics, LLC	Granted
148570.013	11	United States of America	11/937966	09-Nov-2007	8076290	13-Dec-2011	28-Feb-2028	STABILIZING ALKYLGLYCOSIDE COMPOSITIONS AND METHODS THEREOF	Aegis Therapeutics, LLC	Granted

Case Number	Sub Case	Country	Application No.	Filing Date	Patent No.	Issue Date	Expiration / Expected Expiration Date (if pending)	Title	Owner Name	Status
148570.013	21	United States of America	12/050038	17-Mar-2008	8084022	27-Dec-2011	29-Apr-2027	STABILIZING ALKYLGLYCOSIDE COMPOSITIONS AND METHODS THEREOF	Aegis Therapeutics, LLC	Granted
148570.013	31	United States of America	12/119378	12-May-2008	7998927	16-Aug-2011	15-Nov-2026	STABILIZING ALKYLGLYCOSIDE COMPOSITIONS AND METHODS THEREOF	Aegis Therapeutics, LLC	Granted
148570.013	41	United States of America	12/360758	27-Jan-2009	8133863	13-Mar-2012	09-Sep-2027	STABILIZING ALKYLGLYCOSIDE COMPOSITIONS AND METHODS THEREOF	Aegis Therapeutics, LLC	Granted
148570.013	51	United States of America	12/896640	01-Oct-2010	8772231	08-Jul-2014	19-Aug-2026	STABILIZING ALKYLGLYCOSIDE COMPOSITIONS AND METHODS THEREOF	Aegis Therapeutics, LLC	Granted
148570.013	61	United States of America	12/618558	13-Nov-2009	8226949	24-Jul-2012	07-Jun-2027	STABILIZING ALKYLGLYCOSIDE COMPOSITIONS AND METHODS THEREOF	Aegis Therapeutics, LLC	Granted
148570.013	71	United States of America	13/544851	09-Jul-2012	8846044	30-Sep-2014	26-Nov-2026	STABILIZING ALKYLGLYCOSIDE COMPOSITIONS AND METHODS THEREOF	Aegis Therapeutics, LLC	Granted
148570.013	81	United States of America	14/494990	24-Sep-2014	9446134	20-Sep-2016	23-Jun-2026	STABILIZING ALKYLGLYCOSIDE COMPOSITIONS AND METHODS THEREOF	Aegis Therapeutics, LLC	Granted

Case Number	Sub Case	Country	Application No.	Filing Date	Patent No.	Issue Date	Expiration / Expected Expiration Date (if pending)	Title	Owner Name	Status
148570.013	91	United States of America	15/264393	13-Sep-2016	10046025	14-Aug-2018	23-Jun-2026	STABILIZING ALKYLGLYCOSIDE COMPOSITIONS AND METHODS THEREOF	Aegis Therapeutics, LLC	Granted
148570.022	41OB	United States of America	14/133350	18-Dec-2013	9895444	20-Feb-2018	11-May-2025	COMPOSITIONS FOR DRUG ADMINISTRATION	Aegis Therapeutics, LLC	Granted
148570.022	01OB	United States of America	15/942110	30-Mar-2018	10265402	23-Apr-2019	11-May-2025	ABSORPTION ENHANCERS FOR DRUG ADMINISTRATION	Aegis Therapeutics, LLC	Granted
148570.022	21OB	United States of America	16/898365	10-Jun-2020			11-May-2025	ABSORPTION ENHANCERS FOR DRUG ADMINISTRATION	Aegis Therapeutics, LLC	Pending
148570.023	11	United States of America	12/491932	25-Jun-2009	8173594	08-May-2012	24-May-2027	STABILIZING ALKYLGLYCOSIDE COMPOSITIONS AND METHODS THEREOF	Aegis Therapeutics, LLC	Granted
148570.028	01	United States of America	16/311944	20-Dec-2018			26-Jun-2037	COMPOSITIONS, DEVICES AND METHODS FOR THE TREATMENT OF ALCOHOL USE DISORDER	Aegis Therapeutics, LLC; Opiant Pharmaceuticals, Inc.	Pending
148570.029	11	United States of America	17/024149	17-Sep-2020			09-Nov-2037	COMPOSITIONS, DEVICES, AND METHODS FOR THE TREATMENT OF OPIOID-RECEPTOR-	Aegis Therapeutics, LLC; Opiant Pharmaceuticals, Inc.	Pending

Case Number	Sub Case	Country	Application No.	Filing Date	Patent No.	Issue Date	Expiration / Expected Expiration Date (if pending)	Title	Owner Name	Status
								MEDIATED CONDITIONS		
148570.030	01	United States of America	16/461354	15-May-2019			09-Nov-2037	COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPIOID OVERDOSE	Aegis Therapeutics, LLC; Opiant Pharmaceuticals, Inc.	Pending
148570.031	01	United States of America	17/055647	16-Nov-2020			15-May-2039	FORMULATIONS AND METHODS FOR THE PREVENTION OF OPIOID OVERDOSE	Aegis Therapeutics, LLC; Opiant Pharmaceuticals, Inc.	Pending
148570.032	01	United States of America	16/721872	19-Dec-2019			26-Jun-2037	COMPOSITIONS, DEVICES, AND METHODS FOR THE TREATMENT OF OVERDOSE AND REWARD-BASED DISORDERS	Aegis Therapeutics, LLC; Opiant Pharmaceuticals, Inc.	Pending
148570.033	01	United States of America	16/615362	20-Nov-2019			25-May-2038	PEPTIDE COMPOSITIONS AND METHODS OF USE	Aegis Therapeutics, LLC*	Pending
148570.034	01	United States of America	15/890131	06-Feb-2018	10576156	03-Mar-2020	06-Feb-2038	COMPOSITIONS FOR DRUG ADMINISTRATION	Aegis Therapeutics, LLC	Granted
148570.034	21-S	United States of America	16/420044	22-May-2019	10682414	16-Jun-2020	06-Feb-2038	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	Aegis Therapeutics, LLC	Granted
148570.034	41	United States	16/678347	08-Nov-2019			06-Feb-2038	COMPOSITIONS FOR DRUG	Aegis Therapeutics, LLC	Pending

Case Number	Sub Case	Country	Application No.	Filing Date	Patent No.	Issue Date	Expiration / Expected Expiration Date (if pending)	Title	Owner Name	Status
		of America						ADMINISTRATION		
148570.034	51-S	United States of America	16/869461	07-May-2020			06-Feb-2038	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	Aegis Therapeutics, LLC	Pending
148570.035	01	United States of America	16/875683	15-May-2020			15-May-2040	OIL-SOLUBLE DRUG CONTAINING COMPOSITIONS AND METHODS OF USE THEREOF	Aegis Therapeutics, LLC	Pending
148570.035	02	Patent Cooperation Treaty	PCT/US 2020/033201	15-May-2020			16-Nov-2021	OIL-SOLUBLE DRUG CONTAINING COMPOSITIONS AND METHODS OF USE THEREOF	Aegis Therapeutics, LLC	Pending
148570.036	00	United States of America	63/115845	19-Nov-2020			19-Nov-2021	NON-AQUEOUS INTRANASAL DRUG COMPOSITIONS AND METHODS OF THEIR USE	Aegis Therapeutics, LLC	Pending
148570.037	00	United States of America	63/135291	08-Jan-2021			08-Jan-2022	METHODS AND COMPOSITIONS FOR RAPID DELIVERY OF ANTI-SEIZURE THERAPEUTICS	Neurelis, Inc.	Pending
148570.039	00	United States of America	63/115847	19-Nov-2020			19-Nov-2021	PARENTERAL DRUG COMPOSITIONS AND METHODS OF THEIR USE	Aegis Therapeutics, LLC	Pending
148570.040	00	United States	63/115848	19-Nov-2020			19-Nov-2021	NON-AQUEOUS TOPICAL	Aegis Therapeutics, LLC	Pending

Case Number	Sub Case	Country	Application No.	Filing Date	Patent No.	Issue Date	Expiration / Expected Expiration Date (if pending)	Title	Owner Name	Status
		of America						DRUG COMPOSITIONS AND METHODS OF USE		
148570.041	00	United States of America	63/115849	19-Nov-2020			19-Nov-2021	NON-AQUEOUS ORAL DRUG COMPOSITIONS AND METHODS OF USE	Aegis Therapeutics, LLC	Pending
148570.042	31	United States of America	12/266529	06-Nov-2008	8530463	10-Sep-2013	16-Jun-2030	MULTIMODAL PARTICULATE FORMULATIONS	Aegis Therapeutics, LLC; Neurelis, Inc.	Granted
148570.042	61	United States of America	16/594897	07-Oct-2019			07-May-2028	MULTIMODAL PARTICULATE FORMULATIONS	Aegis Therapeutics, LLC; Neurelis, Inc.	Pending
148570.043	21OB	United States of America	13/495942	13-Jun-2012	8895546	25-Nov-2014	27-Mar-2029	ADMINISTRATION OF BENZODIAZEPINE COMPOSITIONS	Neurelis, Inc.	Granted
148570.043	31OB	United States of America	14/527613	29-Oct-2014	9763876	19-Sep-2017	27-Mar-2029	ADMINISTRATION OF BENZODIAZEPINE COMPOSITIONS	Neurelis, Inc.	Granted
148570.043	51OB	United States of America	17/228514	12-Apr-2021			27-Mar-2029	ADMINISTRATION OF BENZODIAZEPINE COMPOSITIONS	Neurelis, Inc.	Pending
148570.043	61OBPE	United States of America	17/332800	27-May-2021			27-Mar-2029	ADMINISTRATION OF BENZODIAZEPINE COMPOSITIONS	Neurelis, Inc.	Pending

Case Number	Sub Case	Country	Application No.	Filing Date	Patent No.	Issue Date	Expiration / Expected Expiration Date (if pending)	Title	Owner Name	Status
148570.043	71OB	United States of America	17/336389	02-Jun-2021			13-Jun-2032	ADMINISTRATION OF BENZODIAZEPINE COMPOSITIONS	Neurelis, Inc.	Pending
148570.044	00	United States of America	63/209089	10-Jun-2021			10-Jun-2022	INTRANASAL OLANZAPINE FORMULATIONS AND METHODS OF THEIR USE	Neurelis, Inc.	Pending
148570.045	00	United States of America	63/185807	07-May-2021			07-May-2022	METHODS AND COMPOSITIONS FOR RAPID DELIVERY OF ANTI-SEIZURE THERAPEUTICS	Neurelis, Inc.	Pending
148570.046	00	United States of America	63/209092	10-Jun-2021			10-Jun-2022	METHODS AND COMPOSITIONS FOR TREATING SEIZURE DISORDERS IN PEDIATRIC PATIENTS	Neurelis, Inc.	Pending
148570.047	01	United States of America	11/065696	24-Feb-2005	7572913	11-Aug-2009	10-Sep-2027	4-SUBSTITUTED PIPERIDINE DERIVATIVES	BioAxone Biosciences, Inc.	Granted
148570.048	01	United States of America	15/006314	26-Jan-2016	9687483	27-Jun-2017	26-Jan-2036	TREATMENT OF CEREBRAL CAVERNOUS MALFORMATIONS AND CEREBRAL ANEURYSMS WITH RHO KINASE INHIBITORS	BioAxone Biosciences, Inc.	Granted
148570.048	11	United States of	15/590815	09-May-2017	10149856	11-Dec-2018	26-Jan-2036	TREATMENT OF CEREBRAL CAVERNOUS MALFORMATIONS AND	BioAxone Biosciences, Inc.	Granted

Case Number	Sub Case	Country	Application No.	Filing Date	Patent No.	Issue Date	Expiration / Expected Expiration Date (if pending)	Title	Owner Name	Status
		America						CEREBRAL ANEURYSMS WITH RHO KINASE INHIBITORS		
148570.048	21	United States of America	16/214973	10-Dec-2018	10857157	08-Dec-2020	26-Jan-2036	TREATMENT OF CEREBRAL CAVERNOUS MALFORMATIONS AND CEREBRAL ANEURYSMS WITH RHO KINASE INHIBITORS	BioAxone Biosciences, Inc.	Granted
148570.048	31	United States of America	17/114335	07-Dec-2020			26-Jan-2036	TREATMENT OF CEREBRAL CAVERNOUS MALFORMATIONS AND CEREBRAL ANEURYSMS WITH RHO KINASE INHIBITORS	BioAxone Biosciences, Inc.	Pending
148570.049	01	United States of America	15/591039	09-May-2017	10106525	23-Oct-2018	09-May-2037	RHO KINASE INHIBITOR BA-1049 (R) AND ACTIVE METABOLITES THEREOF	BioAxone Biosciences, Inc.	Granted
148570.049	11	United States of America	15/988736	24-May-2018	10526313	07-Jan-2020	09-May-2037	RHO KINASE INHIBITOR BA-1049 (R) AND ACTIVE METABOLITES THEREOF	BioAxone Biosciences, Inc.	Granted
148570.049	21	United States of America	16/735359	06-Jan-2020			09-May-2037	RHO KINASE INHIBITOR BA-1049 (R) AND ACTIVE METABOLITES THEREOF	BioAxone Biosciences, Inc.	Pending
148570.050	01	United States of America	16/032442	11-Jul-2018	10537567	21-Jan-2020	11-Jul-2038	KINASE INHIBITORS FOR TREATMENT OF DISEASE	BioAxone Biosciences, Inc.	Granted

Item B. Patent Licenses.

Amended and Restated License Agreement (the “Aegis License”) dated April 19, 2012, by and between the Company and Aegis.

Licensing Agreement by and between the UAB Research Foundation and Aegis, dated as of February 12, 2004, as amended by the First Amendment to Licensing Agreement, dated as of August 30, 2007 and the Second Amendment to Licensing Agreement, dated as of November 6, 2014 (the “Aegis-UAB License”).

Manufacture and Supply Agreement between Aegis, on the one hand, and Inalco Biochemicals, Inc. and Inalco S.p.A., on the other hand, dated as of December 19, 2019 (the “Inalco Agreement”).

Collaboration Agreement by and between Aegis and Accelelevation, LLC, dated as of May 23, 2012 (the “Accelelevation Agreement”).

License Agreement by and between Aegis and Opiant Pharmaceuticals, Inc. (“Opiant”), dated as of January 1, 2017 (the “Opiant License”).

Supply Agreement by and between Aegis and Promius Pharma LLC (“Promius”), dated as of October 29, 2018 (the “Promius Supply Agreement”).

Manufacture and Supply Agreement by and between Aegis and DRL effective as of August 26, 2014 (the “DRL Supply Agreement”).

Amended and Restated License Agreement, by and between Aegis and DRL, dated as of July 19, 2019 (the “USL License”), together with the Side Agreement, by and between Aegis, DRL and USL, dated as of July 19, 2019.

License Agreement by and between Aegis and ARS Pharmaceuticals, Inc. (“ARS”), dated as of June 18, 2018 (the “ARS License”).

Material Transfer Agreement, dated as of July 17, 2019, between Aegis and Biohaven Pharmaceutical Holding Company Ltd. (the “Biohaven MTA”).

Technology Transfer Agreement, dated as of October 11, 2019, between Aegis and Eli Lilly and Company (the “Eli Lilly Agreement”).

Material Transfer Agreement, dated as of December 18, 2020, between Aegis and West Therapeutic Development, LLC (the “West MTA”).

License Agreement, dated as of December 18, 2020, between Aegis and West Therapeutic Development, LLC (the “West License”).

License Agreement, dated as of December 18, 2020, by and among Aegis, BTCP Pharma, LLC and West Therapeutic Development, LLC (the “BTCP License”).

License Agreement, dated as of March 15, 2021, by and among Aegis and Diodem Therapeutics, LLC (the “Diodem License”).